Dodick, David W <br/><br/>
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.  [electronic resource] 

 -  Headache  Jun 2010 
 - 921-36 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1526-4610 
<br/><br/><label>Standard No.: </label>10.1111/j.1526-4610.2010.01678.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Botulinum Toxins, Type A--therapeutic use<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Intention to Treat Analysis<br/>Male<br/>Middle Aged<br/>Migraine Disorders--therapy<br/>Patient Compliance<br/>Patient Selection<br/>Quality of Life<br/>Severity of Illness Index<br/>Treatment Outcome